Fibromyalgia is a long-term chronic condition that causes widespread pain in the muscles and soft tissues throughout the body. The illness can affect people of all ages and has a major impact on quality of life, often making even simple, everyday activities difficult. With an estimated 2–8% of the global population affected, the search for treatments that are both effective and affordable could be a game changer for how symptoms are managed for millions of people who live with the condition.
In a recent study published in JAMA Network Open, researchers compared amitriptyline, an off-label medication that has not been specifically approved by the US FDA for treating fibromyalgia but is often prescribed for it, with three newer medications that are FDA-approved for this condition: pregabalin, duloxetine, and milnacipran.
In search of the better drug
Beyond its impact on patients’ health, fibromyalgia also creates a huge financial burden for both the patients and the government. Medical costs for people with the condition are nearly three times higher than for those without it, and lost productivity related to fibromyalgia accounts for more than 1% of the USA’s GDP.
Despite it being a huge issue with a global market estimated at $3.6 billion annually, only three medications are officially approved by the U.S. FDA: pregabalin (approved in 2007), duloxetine (2008), and milnacipran (2009).
The American College of Rheumatology, however, also recognizes amitriptyline—an older antidepressant—as a viable choice for symptom relief and is often widely used as off-label. This perception was resonated in recent studies that have found that amitriptyline can match the performance of newer therapies.
The researchers in this study focused on a simple yet important question: when real-world costs like productivity and daily functioning are factored in, how does amitriptyline compare with FDA-approved fibromyalgia drugs? It’s an important gap to address, given the medication’s widespread use.
The team followed a group of adults with moderate to severe fibromyalgia and used a mathematical tool called Markov modeling to simulate how a disease progresses over time and predicted long-term costs and quality of life for each treatment across their lifetime.
In the analysis, duloxetine at 120 mg was the most cost-effective option, followed by pregabalin at 450 mg, which outperformed the other drugs when real-world costs were considered. Amitriptyline performed better than milnacipran and lower doses of duloxetine and pregabalin, but it was ultimately surpassed by duloxetine and pregabalin in both health and cost benefits.
The researchers believe that the findings can provide clearer guidance on which treatments deliver the most benefit for the cost, helping shape smarter care for patients with moderate to severe fibromyalgia.
Reference: here
